基于病例报告文献的妊娠期使用磺达肝癸钠安全性分析

打开文本图片集

中图分类号R969.3；R973 文献标志码A 文章编号 00-0408（2025）09-099-06

DOI0.6039/j.issn.00-0408.2025.09.4

ABSTRACTOBJECTIVEToevaluate thesafetyoffondaparinux inpregnancyandprovidereferenceforitsrational clinical application.METHODSAsearch wasconducted indatabases including CNKI，Wanfang，PubMed，Embase，andElsevier（the searchtimewasfromtheconstructionofthedatabasetoDecember17，2024）tocollctcasereportliteratureonfondapariuxuse duringpregnancy.Patientdemographicinformation，fondaparinuxuseduringpregnancy，concomitantmedications，clinical manifestations，andtreatment detailswereextractedfordescriptivestatisticalanalysis.RESULTSAtotalof17casereports regardingtheuseoffondaparinux during pregnancywerecolected，involving42patientsfrom1lcountriesand47pregnancy records.Amongthese，2Ocasesinvolvedtheuseoffondaparinuxforthepreventionofpregnancy-relatedvenous thromboembolism （VTE），while27cases werefondaparinux treatmentduetorelatedconditions.Atotalof29occurencesoftepatientsweretreated with fondapariuxduetoa（family）historyofVTE.Nineoccurencesofcomplicated pregnancieswerereported，and35patients hadecordsofcomorbiditiesorrelevant medical histories.Theadverseeventsthatocurredduringpregnancywiththeuseof fondaparinux includepostpartum hemorrhage（7cases）andexcesiveanticoagulationcausedbyinappropriate dosage（1case）.

Among the 7 casesof postpartum hemorrhage，3 caseshada blood loss of no less than 1 0 0 0 m L （including 2 cases with uterine atony），3 cases had a drug discontinuation time of ⩽ 1 2 h CONCLUSIONS Based on the existing literature，the safetyoffondaparinuxduringpregnancyisgenerally manageable，with the main adverse event being postpartum hemorrhage.The dosage，interval between discontinuation， comorbidities/medical history，andconcomitantmedicationsof fondaparinux may be the main causesof its adverse events.

KEYWORDSfondaparinux; pregnancy； safety evaluation;anticoagulation；casereport；literatureanalysis

妊娠期女性与非妊娠期女性相比，发生静脉血栓栓塞（venousthromboembolism，VTE）的风险约增加了5倍；而在产褥期，该风险进一步增加至20倍以上，且一直持续到产后12周。（剩余12143字）